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Abstract
Background: Ectopic fat deposition in liver and skeletal muscle tissue is related to cardiovascular disease risk and is
a common metabolic complication in obese children. We evaluated the hypotheses of ectopic fat in these organs
could be diminished following 1 year of multidisciplinary care specialized in childhood obesity, and whether this
reduction would associate with changes in other markers of metabolic function.
Methods: This observational longitudinal study evaluated 40 overweight children and adolescents enrolled in a
multidisciplinary treatment protocol at the Children’s Obesity Clinic, Holbæk, Denmark. The participants were assessed
by anthropometry, fasting blood samples (HbA1c, glucose, insulin, lipids, and biochemical variables of liver function),
and liver and muscle fat content assessed by magnetic resonance spectroscopy at enrollment and following an
average of 12.2 months of care. Univariate linear regression models adjusted for age, sex, treatment duration,
baseline degree of obesity, and pubertal developmental stage were used for investigating possible associations.
Results: The standard deviation score (SDS) of baseline median body mass index (BMI) was 2.80 (range: 1.49–3.85) and
the median age was 14 years (10–17). At the end of the observational period, the 40 children and adolescents (21 girls)
significantly decreased their BMI SDS, liver fat, muscle fat, and visceral adipose tissue volume. The prevalence of
hepatic steatosis changed from 28 to 20 % (p = 0.26) and the prevalence of muscular steatosis decreased from 75
to 45 % (p = 0.007).
Changes in liver and muscle fat were independent of changes in BMI SDS, baseline degree of obesity, duration of
treatment, age, sex, and pubertal developmental stage.
Conclusions: A 1-year multidisciplinary intervention program in the setting of a childhood obesity outpatient clinic
confers a biologically important reduction in liver and muscle fat; metabolic improvements that are independent of the
magnitude of concurrent weight loss.
Trial registration: ClinicalTrials.gov registration number: NCT00928473, the Danish Childhood Obesity Biobank.
Registered June 25, 2009.
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Background
Hepatic and muscular steatosis are common metabolic
abnormalities in obese children [1, 2]. Childhood onset
accumulation of ectopic fat in liver and skeletal muscle
indicates an increased cardiovascular disease risk includ-
ing dyslipidemia and insulin resistance [3–8], the latter
being a metabolic abnormality that precedes the devel-
opment of type 2 diabetes [9].
Several methods can assess the content of ectopic
lipid accumulation, including computed tomography,
ultrasound, tissue biopsies, proton magnetic resonance
spectroscopy (MRS), and magnetic resonance imaging
(MRI) [10]. The non-invasive and non-ionizing MRS is
considered gold standard in muscle lipid quantification
[10] and may in the future replace liver biopsies as the
gold standard in the quantification of liver fat, although
it is not providing information regarding histological al-
terations [10–12].
Studies on treatment of ectopic fat accumulation in
childhood mainly address hepatic steatosis and the exist-
ing literature proposes lifestyle intervention and weight
loss as the therapeutics of choice [13, 14]. Despite the
increasing prevalence in pediatric hepatic steatosis, a tar-
geted treatment strategy of this condition has yet to be
established, and the potential future increase in a broad
array of liver and muscular steatosis-related morbid-
ities calls for further progress in this field of research
[13, 14].
The outlined multidisciplinary care protocol to combat
obesity has previously been reported to associate with
reduction of body mass index (BMI) standard deviation
score (SDS) in a study of 492 overweight and obese chil-
dren and youths [15] and with improved fasting serum
lipid profiles in a study of 240 overweight and obese
children and youths [16].
The objective of this 1-year observational study was to
investigate the impact of the multidisciplinary care proto-
col practiced in our outpatient clinic of childhood obesity
with a focus on changes in ectopic deposition of fat in
the liver and skeletal muscles. We hypothesized that ec-
topic fat in these organs could be reduced following 1
year of childhood obesity treatment, and that this re-




From August 2009 to October 2014, 1406 overweight
children and adolescents were enrolled in treatment at
The Children’s Obesity Clinic, Department of Pediatrics,
Copenhagen University Hospital Holbæk, Denmark [15].
Of these, 398 were offered an MR-scan at the time of
treatment start, and hereof 92 were subsequently offered
a follow-up MR-scan after 1 year of treatment. The
inclusion criteria were i) 8–18 years of age at enroll-
ment, ii) enrollment in childhood obesity treatment, iii)
each of the two MR assessments of liver and muscle
lipid accumulation (at baseline and at follow-up) should
have concomitant anthropometric and biochemical mea-
sures within a 60 days period, and iv) a baseline BMI
SDS above 1.28, which corresponds to the 90th percent-
ile according to Danish age- and sex-adjusted references
[17]. The exclusion criteria were i) a body weight above
135 kg, which was the maximum capacity of the MR
scanner, ii) inability to remain quiet in the MR machine
during the 45 minutes scan time, iii) presence of other
liver diseases, iv) development of type 2 diabetes mellitus
during the treatment period, or v) an alcohol consump-
tion of more than 140 g/week.
Treatment
The Children’s Obesity Clinic is a chronic care, multidis-
ciplinary, best-practice, hospital-based, outpatient, child-
hood obesity treatment center involving a staff core
of pediatricians, dieticians, nurses, psychologists, social
workers, secretaries, and research technicians [15]. Some
baseline examinations are performed as in-patient admis-
sions. Children and adolescents are referred for treatment
from their general practitioners, school- and commu-
nity based doctors, or pediatricians (at hospitals or pri-
vate practices) from all over Denmark. At inclusion, a
pediatrician sees the child and family for 1 hour, where
the medical history and a physical examination of the
child are performed. At this visit the child and family
are introduced to the treatment protocol, which is a
family-centered approach involving behavior-modifying
techniques, where the child and family receive an indi-
vidually tailored and thorough plan of lifestyle advices
[15]. This plan addresses sugar and fat intake, sources of
nutrition, activity, inactivity, psychosocial capabilities,
disturbed eating behaviors, sleeping disorders, hygiene,
allowances, and more [15]. The child and family are
scheduled to consult a pediatrician on an annual basis
and a pediatric nurse, dietician, and/or psychologist as
needed. The treatment plan is evaluated at every visit.
Each family is on average seen in the clinic every
6.5 weeks, with a mean of 5.4 hours of health profes-
sional time spent on each patient per year [15].
The treatment protocol for the Children’s Obesity
Clinic is described in detail by Holm et al. [15], and the
appendix “Information to the readers” is furthermore
available from the authors.
Anthropometry
Body weight was measured to the nearest 0.1 kg on a
Tanita digital medical scale (WB-100 MA; Tanita Corp.,
Tokyo, Japan). Height was measured to the nearest 1 mm
by a stadiometer. Weight and height were measured with
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bare feet in underwear or light indoor clothing. BMI was
calculated as weight divided by height squared (kg/m2).
The BMI SDS was calculated by the LMS method by con-
verting BMI into a normal distribution by sex and age
using the median coefficient of variation and a measure of
the skewness [18] based on the Box-Cox power plot based
on Danish BMI charts [17].
Pubertal development
The pubertal stage was determined at baseline by a trained
pediatrician using the classification of Tanner [19]. In
boys, the developmental stages of pubic hair and genitals
were determined, and testes size was determined by an
orchidometer. In girls, the developmental stages of breasts
and pubic hair were determined.
MR spectroscopy and imaging
MR measurements were performed on a 3.0 T MR im-
aging system (Achieva, Philips Medical Systems, Best,
The Netherlands) using a SENSE cardiac coil and the
data post processing was performed by an experienced
MR physicist. The participants were examined in the su-
pine position. Liver fat content (LFC) and muscle fat
content (MFC) were measured by MRS. MFC was mea-
sured in the psoas muscle. Visceral adipose tissue (VAT)
and subcutaneous adipose tissue (SAT) volumes were
measured by MRI, assessed from a transverse slice of
10 mm thickness at the level of the third lumbar verte-
bra. The details of the applied methodology of MRI and
MRS have previously been described [1, 2].
Hepatic steatosis was defined as an LFC >5 % [20] and
muscular steatosis was defined as an MFC >5 % [2].
Blood sampling
Blood samples were drawn from an antecubital vein be-
tween 7 a.m. and 9 a.m. after an overnight fast. If re-
quired, an anesthetic cream was applied one hour before
venipuncture. The biochemical analyses of plasma con-
centrations of glucose and serum concentrations of
triglycerides, total cholesterol, high density lipoprotein
(HDL) cholesterol, alanine transaminase, and gamma-
glutamyl transferase were performed on a Dimension
Vista® 1500 analyzer (Siemens, Munich, Germany).
Plasma glucose samples and the serum samples of tri-
glycerides, cholesterol fractions, and biochemical vari-
ables of liver function were stored at room temperature
for less than 30 min after sampling before being centri-
fuged at four degrees Celsius. Plasma glucose samples
were collected in tubes containing fluoride. The bio-
chemical analyses of serum insulin concentrations were
performed on a Cobas® 6000 analyzer (F. Hoffmann-La
Roche Ltd, Basel, Switzerland) and stored at room
temperature for 30–60 min after sampling before being
centrifuged at four degrees Celsius. Analyses of all
plasma and serum samples were performed immedi-
ately after being centrifuged. Insulin samples were col-
lected in a tube containing serum separating gel. The
biochemical analyses of whole blood glycosylated
hemoglobin (HbA1c) were performed on a Tosoh high-
performance liquid chromatography G8 analyzer (Tosoh
Corporation, Tokyo, Japan). The low density lipoprotein
(LDL) cholesterol concentration was calculated as: Total
cholesterol – (triglycerides × 0.45) + HDL cholesterol. The
Non-HDL cholesterol concentration was calculated as:
Total cholesterol – HDL cholesterol.
Statistical analysis
Wilcoxon signed rank test was used to analyze differ-
ences in continuous variables between groups and to
analyze estimations of differences from baseline to follow-
up and the corresponding nonparametric confidence in-
tervals (CI). The differences in fractions of steatosis were
analyzed by McNemar’s Test for paired categorical data.
Associations were investigated by univariate linear regres-
sion models adjusted for age, sex, treatment duration,
baseline degree of obesity, and pubertal developmental
stage. The linear regression analyses were based on the
logarithmically transformed baseline and follow-up values.
P-values were not adjusted for multiple hypothesis testing
and the level of significance was set at p <0.05. Statistical
analyses were performed using “R” statistical software ver-
sion 3.1.2 (http://www.r-project.org).
Ethical aspects
Informed written consent was obtained from the parents
of patients younger than 18 years and from patients of
18 years of age. The study was approved by the Ethics
Committee of Region Zealand, Denmark (SJ-104) and
the Danish Data Protection Agency (REG-06-2014) and
is registered at ClinicalTrials.gov (NCT00928473). This
study has been reported in line with the STROBE guide-
lines (Additional file 1).
Results
Of the 92 who were offered two MRS assessments, 40
overweight and obese children and adolescents fulfilled
the inclusion criteria. Beside these, five patients were ex-
cluded because they had a body weight >135 kg, one pa-
tient was excluded from the study because of the
development of type 2 diabetes mellitus during the study
period, and 46 children and adolescents fulfilled all cri-
teria except for having blood samples drawn within the
60 days period of the MR assessment. None were ex-
cluded due to an inability to stay quiet during the scan
time, other liver diseases, or an alcohol consumption of
more than 140 g/week. The group not complying with
the blood sample criterion were comparable to the 40
included children and adolescents in regards to BMI
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SDS, VAT, SAT, and liver fat content before and after
treatment (data not shown). The 40 overweight/obese
children and adolescents (21 girls) had a baseline median
BMI SDS of 2.80 (range 1.49–3.85) and a median age of
13.7 years (10.0–16.8). MRS, MRI, and concomitant an-
thropometric and biochemical measures were performed
on all study participants at baseline and after a median
of 12 months of follow-up (Table 1). The time between
the MR scan and the biochemical measures was a me-
dian of 10 days (range: 0–58) at baseline and 10 days
(1–59) at follow-up. Blood samples were performed
within 30 days from the anthropometric measures (me-
dian: 12 days), and the time between the MR scan and
the anthropometric measures was a median of 14 days
(range: 0–56) at baseline and 17 days (1–53) at follow-up.
The 1406 children and adolescents included in treat-
ment were 1.5 years younger (95 % CI: 0.6–2.5, p =
0.001) than the 40 included children and adolescents,
but comparable in baseline BMI-SDS (difference: 0.1, CI
95 %: −0.1–0.3, p = 0.23).
Treatment
The characteristics of the 40 overweight and obese chil-
dren and adolescents at baseline and follow-up are shown
in Table 1. After an average of 12.2 months (95 % CI:
11.9–13.1) of treatment, BMI SDS was reduced by 0.23
(95 % CI: 0.10–0.44, p = 0.001) accompanied by reductions
in liver fat percentage (1.0, 95 % CI: 0.3–3.6, p = 0.01),
muscle fat percentage (2.4, 95 % CI: 0.7–4.0, p = 0.01),
and VAT volume (14 cm3, 95 % CI: 3–27, p = 0.01). Fur-
thermore, we observed reductions in concentrations of
whole blood HbA1c by 1.0 mmol/mol (95 % CI: 0.0–
2.0, p = 0.04), fasting serum levels of LDL cholesterol by
0.2 mmol/l (95 % CI: 0.0–0.4, p = 0.02), and non-HDL
cholesterol by 0.2 mmol/l (95 % CI: 0.0–0.4, p = 0.02),
and an increase in fasting serum HDL cholesterol con-
centration of 0.1 mmol/l (95 % CI: 0.0–0.2, p = 0.03).
The individual treatment responses on levels of liver
and muscle fat are shown in the Figs. 1 and 2, respect-
ively. At baseline, the prevalence of hepatic steatosis was
28 %; a fraction that was 20 % at follow-up (p = 0.26)
(Table 1). Two of the 29 (7 %) study patients without
hepatic steatosis at baseline exhibited hepatic steatosis
at follow-up, while five of the 11 (45 %) with hepatic
steatosis at baseline exhibited no hepatic steatosis at
follow-up. Muscular steatosis was reduced from 75 % at
baseline to 45 % at follow-up (p = 0.007) (Table 1). Four
of the ten (40 %) patients without muscular steatosis at
baseline exhibited muscular steatosis at follow-up, while
16 of the 30 (53 %) with muscular steatosis at baseline ex-
hibited no muscular steatosis at follow-up.
We observed no significant changes in fasting concen-
trations of plasma triglyceride, plasma glucose, serum in-
sulin, or biochemical variables of liver function (Table 1).
Table 1 Characteristics of the 40 (21 girls) overweight children and adolescents
Baseline Follow-up p
Age, years 13.7 (10.0–16.8) 14.6 (10.9–17.8) <0.0001***
BMI SDS 2.80 (1.49–3.85) 2.56 (0.18–4.68) 0.001**
VAT, cm3 83 (21–361) 73 (15–396) 0.01*
SAT, cm3 282 (97–518) 262 (74–527) 0.14
LFC, % 3.0 (0.5–67.0) 3.0 (0.5–32.0) 0.01*
Hepatic steatosis, fraction 28 % (11/40) 20 % (8/40) 0.26
MFC, % 7.4 (1.2–26.3) 4.8 (0.5–39.6) 0.01*
Muscle steatosis, fraction 75 % (30/40) 45 % (18/40) 0.007**
Triglyceride, mmol/l 0.9 (0.2–2.3) 1.0 (0.3–2.0) 0.78
HDL cholesterol, mmol/l 1.2 (0.7–1.7) 1.2 (0.8–2.1) 0.03*
LDL cholesterol, mmol/l 2.3 (1.1–4.2) 2.4 (1.0–3.8) 0.02*
Non-HDL cholesterol, mmol/l 2.8 (1.2–4.7) 2.8 (1.2–4.4) 0.02*
Plasma glucose, mmol/l 5.1 (4.2–6.2) 5.1 (4.4–5.9) 0.42
Serum insulin, pmol/l 83 (11–271) 87 (14–226) 0.99
HbA1c, mmol/l 35 (28–42) 34 (26–40) 0.04*
ALT, U/l 22 (11–126) 22 (10–69) 0.67
GGT, U/l 18 (5–134) 16 (9–33) 0.72
Data are medians (range) due to a non-normal distribution
ALT alanine transaminase; BMI body mass index; GGT gamma-glutamyl transferase; HDL high density lipoprotein; HbA1c glycosylated hemoglobin; IMCL intramyo-
cellular lipid content; LDL low density lipoprotein; LFC liver fat content; MFC muscle fat content; SAT subcutaneous adipose tissue volume; SDS standard deviation
score; VAT visceral adipose tissue volume
P value for group differences: *** p <0.001; ** p <0.01; * p <0.05
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Changes in liver fat content
Changes in LFC, adjusted for the baseline level of LFC,
age, sex, treatment duration, baseline degree of obesity,
and pubertal developmental stage, associated positively
with changes in MFC (p = 0.045) and inversely with base-
line levels of liver fat (p = 0.001). Changes in LFC were not
significantly associated with baseline levels of or changes
in BMI SDS (p = 0.30, p = 0.57), VAT (p = 0.47, p = 0.45),
SAT (p = 0.27, p = 0.21), or fasting concentrations of tri-
glycerides (p = 0.49, p = 0.78), HDL cholesterol (p = 0.83,
p = 0.62), LDL cholesterol (p = 0.67, p = 0.06), non-HDL
cholesterol (p = 0.63, p = 0.07), plasma glucose (p = 0.66,
p = 0.67), serum insulin (p = 0.07, p = 0.12), HbA1c (p =
0.61, p = 0.50), alanine transaminase (p = 0.87, p = 0.16),
or gamma-glutamyl transferase (p = 0.83, p = 0.16).
While the group not exhibiting hepatic steatosis at base-
line maintained the degree of LFC (median change: −0.1 %,
(interquartile range: −0.7; 0.5)), the group exhibiting hep-
atic steatosis decreased the LFC by a median −7.8 %
(−22.0; −3.4) (p-value for difference: p = 0.0003).
Changes in muscle fat content
Changes in MFC, adjusted for the baseline level of MFC,
age, sex, treatment duration, baseline degree of obesity,
and pubertal developmental stage, associated positively
with changes in VAT (p = 0.001) and inversely with base-
line levels of MFC (p = 0.0005). Changes in MFC were
not significantly associated with baseline levels of or
changes in BMI SDS (p = 0.17, p = 0.36), LFC (p = 0.25,
p = 0.47), SAT (p = 0.15, p = 0.57), or fasting concentra-
tions of triglycerides (p = 0.11, p = 0.86), HDL choles-
terol (p = 0.85, p = 0.45), LDL cholesterol (p = 0.11, p =
0.28), non-HDL cholesterol (p = 0.07, p = 0.24), plasma
Fig. 1 Liver Fat Development during Treatment. The development of liver fat content for the individual study participants during an average
follow-up of 12.2 months
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glucose (p = 0.66, p = 0.37), serum insulin (p = 0.53, p =
0.21), or HbA1c (p = 0.06, p = 0.52).
While the group not exhibiting muscular steatosis at
baseline tended to increase the degree of MFC (median
change: 2.1 %, (interquartile range: −0.5; 3.6)), the group
exhibiting muscular steatosis decreased the MFC by a me-
dian −3.4 % (−7.0; −1.6) (p-value for difference: p = 0.74).
Only the inverse associations between the change in
and the baseline level of both LFC and MFC remained
significant after adjusting for multiple testing ad modum
Benjamini & Hochberg (data not shown).
Discussion
This 1-year multidisciplinary intervention program asso-
ciated with a biologically important reduction in liver
and muscle fat as assessed by magnetic resonance mea-
sures. Comparable findings of concomitant reductions in
BMI SDS, MRI-measured liver fat, and waist circumfer-
ence (as a surrogate measure of visceral fat) have been
reported in a 1-year nutrition-behavior intervention
study of 26 obese children with an age of 6–14 years
[21]. The present study extends these findings by report-
ing reductions in ectopic fat content in liver and muscle
independent of the magnitude of weight loss. In a 12-
week exercise intervention study of 15 obese and 14 lean
post-pubertal adolescents, van der Heijden et al. [22] ob-
served reductions in MRS-measured liver fat, but with-
out reductions in intramyocellular lipids (IMCL) or BMI
SDS suggesting the beneficial effect of longer treatment
periods, as observed in the present study.
In two multidisciplinary childhood obesity treatment
programs of 6 and 12 months duration, respectively, Koot
et al. [23] in a study of 144 children and adolescents and
Reinehr et al. [24] in a study of 109 children and
Fig. 2 Muscle Fat Development during Treatment. The development of muscle fat content for the individual study participants during an average
follow-up of 12.2 months
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adolescents reported reductions in ultrasound-measured
LFC and BMI SDS. Compared to MRS, ultrasonographic
longitudinal studies have some limitations since they pro-
vide less precise and reproducible quantitative information
and have great inter- and intraobserver variability [25]. Al-
though both studies used a single experienced observer,
Koot et al. [23] still reported an intraobserver agreement
as low as 57 %, whereas Reinehr et al. [24] did not report
observer variability.
A study on seven adults reported a reduction in MRS-
measured IMCL during 9 weeks of dietary weight loss
intervention [26], while a 12-week dietary weight loss
intervention of 13 non-diabetic obese adults found no
reductions in MRS-measured IMCL [27]. These differ-
ences might reflect a considerable variability in the accu-
mulation of fat in muscle tissue, which is also suggested
in the 40 % of the present study participants who shifted
from no muscular steatosis to muscular steatosis, although
we observed a significant majority of the patients shifting
from muscular steatosis to no steatosis (Fig. 2). Further-
more, in ten obese adults, a 6 months weight loss inter-
vention reduced MRS-measured IMCL in the mainly
glycolytic tibialis muscle [28], but not in the mainly oxida-
tive soleus muscle, despite that glycolytic muscles, includ-
ing the psoas muscle, generally contain lower amounts of
fat as compared to oxidative muscles [29, 30].
Glucose metabolism
Associations between the accumulation of fat in skeletal
muscle and dysregulation of the glucose metabolism have
been reported in both cross-sectional [31] and longitu-
dinal studies [26].
In a weight loss study of seven overweight adults
undergoing dietary intervention alone compared to nine
overweight adults undergoing combined dietary and ex-
ercise intervention, Toledo et al. reported comparable
changes in weight loss and insulin sensitivity in the two
groups, while biopsy-proven IMCL was reduced only in
the dietary intervention group [32]. This suggests that
muscle lipid accumulation is independent of insulin sen-
sitivity, which is also suggested in the study by van der
Heijden et al. where insulin sensitivity improved without
reductions in IMCL [22].
The relationship between fatty liver and elevated fast-
ing circulating levels of glucose and insulin has been
reported in cross-sectional studies [4, 5]. In the afore-
mentioned intervention study by van der Heijden et al,
reductions in liver and visceral fat correlated with re-
ductions in circulating insulin concentrations in the
group of obese adolescents [22]. Several longitudinal
studies of reductions in LFC assessed by ultrasound
have shown concomitant improvements in glucose me-
tabolism in 144, 84, 71, and 20 children and adoles-
cents, respectively [23, 33–35], suggesting a positive
association between LFC and insulin resistance. In con-
trast, Pozzato et al. [21] and Reinehr et al. [24] did not
observe any associations between changes in liver fat
and changes in fasting glucose or insulin levels, despite
comparable sample sizes. In the present study, no re-
ductions were seen in either fasting insulin or glucose,
despite improvements in a range of other metabolic
markers. This is most likely due to a majority of study
participants undergoing puberty during the treatment
period, and the transitory physiological insulin resist-
ance (worsening glucose metabolism) in the pubertal
period that potentially overshadows any improvements
resulting from the treatment [36]. Nonetheless, we did
observe reductions in HbA1c in the present study.
Lipid metabolism
Cross-sectional studies in children and adolescents have
reported positive associations between serum lipid pro-
files and steatosis in liver [37] and muscle [38]. Longitu-
dinal pediatric studies have shown relationships between
lipid profiles and hepatic steatosis [23] and liver fibrosis
[33] - a complication to hepatic steatosis - although
none of these associations remained significant in
multivariate analyses [23, 33]. In two longitudinal stud-
ies on concomitant changes in MFC and serum lipid
variables in adults, no significant associations have been
reported [26, 27]. Although improvements in the gen-
eral serum lipid profile were observed in the present
study, no significant association to ectopic fat in liver
and muscle were observed.
Relationship between the ectopic fat depots
The deposition of lipids in the ectopic fat depots is
thought to take place when the capacity of the subcuta-
neous adipose tissue is exceeded [3]. Positive correla-
tions have previously been reported between LFC and
VAT [1, 27, 28], MFC and VAT [2], and between LFC
and MFC [5], suggesting that storage and mobilization
of lipids in these ectopic depots are interconnected.
These findings are in line with results in the present
study, except for the lack of association between LFC
and VAT. In the present study, we furthermore observed
that the changes in ectopic fat content in liver and muscle
were inversely associated with their respective baseline
levels, suggesting that individuals with a higher level of ec-
topic tissue fat at the baseline exhibited greater reductions
in ectopic fat content during treatment. This observation
may be (partly) explained by the phenomenon ‘regression
towards the mean’.
Biochemical markers of liver function
Changes in LFC have been positively associated with
changes in alanine transaminase and gamma-glutamyl
transferase in childhood obesity treatment [39] of a
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comparable sample size to the present study. Even
though childhood obesity has been linked to fatty liver
[40] and elevated concentrations of liver enzymes [41],
the measures of variables serving as proxies for liver
function may deviate from and potentially underestimate
pathological histological alterations in the liver [42]. In
line with the latter, we observed no relationships be-
tween liver fat changes and baseline or follow-up levels
of liver function markers.
Strengths and limitations
A strength of the present protocol is the relatively high
number of participants with simultaneous MRS-assessed
fat content in liver and muscle and concomitant mea-
sures of anthropometrics and pertinent fasting biochem-
ical blood variables measured before and after a 1-year
treatment period in a best-practice based multidisciplin-
ary regimen focused at combating childhood obesity.
One of the major limitations of our study is that not
all measures of biochemistry were assessed on the same
day as the MR scan, hereby allowing natural day-to-day
biological variations to affect the results. Additionally,
most of the MR scans were performed after the start of
intervention, which may have caused an underestimation
of the ectopic fat reducing effect of treatment.
Furthermore, a large part of the children and ado-
lescents assessed by MRS twice were excluded due to
the 60 days limit criterion, why the presented data
might be subject to a selection bias; e.g. that the
study participants might have been more compliant
to the treatment protocol than the excluded children
and adolescents. Unfortunately, such exclusion is dif-
ficult to avoid in a study based on data from clinical
practice, and the proposed time limit is important in
order to justify concomitant changes within the data.
Since the two groups were comparable in body com-
position both before and after treatment, we consid-
ered this selection bias acceptable.
Other limitations include that the sample size and the
small changes in LFC may cause associations in regres-
sion analyses to be missed, and that the analyses of associ-
ations were made without adjusting for multiple testing,
which increases the chance of type I errors. Furthermore,
pubertal developmental stage was only assessed at baseline
and not at follow-up.
Conclusions
Reductions in magnetic resonance spectroscopy measured
liver and muscle fat are attainable in multidisciplinary
childhood obesity treatment, independent of the magni-
tude of weight loss and with concomitant improvements
in lipid and glucose metabolism.
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